This bill — the Flu Vaccine Act — would authorize $1 billion in funding for the creation of a universal influenza vaccine over the next five years. The Director of the National Institute of Allergy and Infectious Diseases would use the funding to conduct or support comprehensive research leading to the vaccine’s creation. A total of $200 million in funding would be authorized for each of fiscal years 2019-2023, up from the $64 million spent in fiscal year 2017 on such research.
- Not enactedThe President has not signed this bill
- The house has not voted
- The senate has not voted
Committee on Health, Education, Labor, and PensionsIntroducedFebruary 15th, 2018
- senate Committees
What is Senate Bill S. 2438?
Cost of Senate Bill S. 2438
In-Depth: Sponsoring Sen. Ed Markey (D-MA) introduced this bill to support $1 billion in research toward a universal influenza vaccine that could be administered once or twice and provide a lifetime of protection:
“America’s scientists and clinicians are gold medalists in health and disease research, and it is up to the United States to lead the world in the response to the flu. We must enhance our ability to predict the right strain for the next season, produce a more optimal vaccine, and protect all Americans against all strains of this virus. The Flu Vaccine Act will help provide dedicated, consistent resources so that we can perform the basic science research necessary to improve upon our current vaccine and ultimately develop a universal one.”
Markey’s press release stated that as of February 15, there had already been 63 pediatric deaths and high levels of hospitalizations related to the flu this season. It added that the flu costs the nation an estimated $10.4 billion in medical costs annually and $87 billion in total economic burden.
This legislation has the support seven cosponsors in the Senate, all of whom caucus as Democrats.
Summary by Eric Revell(Photo Credit: scyther5 / iStock)